HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)
ID: 350461Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $3M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350461

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-037.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity through the HIV Vaccine Research and Design (HIVRAD) Program, aimed at supporting multi-disciplinary projects focused on the discovery of effective prophylactic vaccines against HIV/AIDS. This initiative encourages comprehensive research addressing critical scientific questions related to immune responses, vaccine vectors, and the evaluation of vaccine concepts in non-human primate models. The program anticipates funding 1-2 awards with a total budget of approximately $5 million for fiscal year 2025, with projects eligible for a maximum duration of five years. Interested applicants must comply with the NIH Data Management and Sharing Policy and submit their applications by March 13, 2026. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-037.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-037-Full-Announcement.html
    PAR-24-037.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is announcing the HIV Vaccine Research and Design (HIVRAD) Program intended to support comprehensive projects focused on developing effective prophylactic vaccines against HIV/AIDS. This Notice of Funding Opportunity (NOFO) encourages multi-disciplinary research addressing critical questions in vaccine discovery. It aims to investigate various aspects such as immune responses, vaccine vectors, and the use of non-human primate models. Eligible entities include higher education institutions, nonprofits, and various government entities. The program will fund 1-2 awards with a budget totaling approximately $5 million for fiscal year 2025, supporting projects for a maximum of five years. Applications must comply with the NIH Data Management and Sharing Policy, include a specific Plan for Enhancing Diverse Perspectives (PEDP), and are due by specified deadlines. The overall impact rating will consider significance, innovation, investigator qualifications, and project approach, ensuring a collaborative and scientific environment conducive to groundbreaking research. This initiative reflects NIH's ongoing commitment to addressing public health needs related to HIV prevention through robust scientific inquiry and innovation.
    Similar Opportunities
    Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Innovation for HIV Vaccine Discovery" (NOFO Number PAR-23-169) aimed at supporting high-risk, high-impact early discovery research focused on innovative vaccine approaches to prevent HIV acquisition and ongoing infection. This initiative emphasizes a Go/No-Go funding approach, requiring applicants to demonstrate measurable progress towards defined goals by the end of Year 2, with continued funding contingent upon meeting these criteria. The overall budget for this initiative is approximately $2 million for fiscal year 2024, with individual project budgets capped at $350,000 per year, and applications must be submitted via Grants.gov by August 2, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled the Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD), aimed at advancing HIV-1 vaccine candidates from preclinical studies to clinical trial readiness. This program supports a range of activities including immunogenicity studies, manufacturing processes, and regulatory compliance, with a focus on innovative vaccine technologies that can elicit broadly neutralizing antibodies. The funding opportunity is significant in addressing ongoing health challenges related to the HIV/AIDS epidemic, with an award ceiling of $3 million and applications due by March 14, 2025. Interested applicants can find more information and submission details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models," aimed at supporting preclinical research on HIV/AIDS conducted by early-stage investigators with at least two years of postdoctoral experience. This funding initiative encourages innovative research approaches utilizing NHP models to develop next-generation therapies and strategies for HIV cure, aligning with the NIH Strategic Plan priorities for HIV research. Eligible applicants can request up to $200,000 in direct costs annually, with a total budget cap of $400,000 over two years, and must adhere to specific application procedures. The application deadline is September 7, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)" to stimulate research aligned with the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This initiative aims to support research on HIV-related comorbidities, gastrointestinal diseases, and metabolic disorders associated with HIV, encouraging applications from a diverse range of organizations, including higher education institutions and non-profits. With an estimated funding of $2 million for fiscal year 2025, the NIH plans to support 3 to 5 selected projects over a maximum project period of five years, with applications undergoing a rigorous peer review process. Interested applicants can find more information and submit their proposals through Grants.gov, with a submission deadline of January 7, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Cellular Models of HIV Pathogenesis within NIDDK Mission Areas (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), has announced a funding opportunity for research focused on developing cellular models of HIV pathogenesis. This initiative aims to enhance understanding of HIV interactions with human tissues by utilizing innovative three-dimensional models, such as organoids and microphysiological systems, to investigate mechanisms of viral persistence and associated co-occurring conditions. The funding opportunity allows for a budget of up to $500,000 annually, with a total commitment of $3 million for the fiscal year 2026, and applications are due by March 20, 2025. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-021.html.
    New Partners Initiative Translational HIV Research for Innovative Vaccines Ecosystem (NPI THRIVE)
    Active
    Agency for International Development
    The United States Agency for International Development (USAID) is inviting applications for the New Partners Initiative Translational HIV Research for Innovative Vaccines Ecosystem (NPI THRIVE), aimed at accelerating the development of a safe and effective HIV vaccine through collaborative research led by African scientists and institutions. This funding opportunity includes at least two cooperative agreements, with a total funding ceiling of $98.5 million over five years, structured around two main objectives: enhancing African-led clinical research and advancing promising immunogens towards first-in-human studies. The program emphasizes innovative, locally-led approaches and is open to a wide range of eligible applicants, including nonprofits without 501(c)(3) status, with a focus on projects predominantly within African countries to leverage local capabilities in addressing global HIV vaccine research challenges. Interested parties must submit a concept paper by January 28, 2025, and can contact Elton Fortson at npithrive@usaid.gov for further information regarding the application process.
    Role of Defective Proviruses in HIV Persistence (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Role of Defective Proviruses in HIV Persistence (R01 Clinical Trial Not Allowed)" aimed at supporting research on the impact of defective HIV proviruses on persistence and pathogenesis during antiretroviral treatment. The objective is to characterize these defective proviruses in human samples, optimize assays to mitigate their influence, and study their effects on viral dynamics, which is crucial for improving HIV cure strategies and understanding chronic immune activation in treated individuals. Eligible applicants include a wide range of institutions, such as public and private nonprofits, higher education entities, and for-profits, with funding available up to $500,000 per year for projects lasting a maximum of five years. Interested parties should note that applications can be submitted starting in April 2025, and all inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    HIV/AIDS Scholars Using Nonhuman Primate (NHP) Models Program (K01 Independent Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the HIV/AIDS Scholars Using Nonhuman Primate (NHP) Models Program (K01), a federal grant opportunity aimed at supporting early-stage investigators in the field of HIV/AIDS translational studies. This program is designed for individuals within ten years of completing their terminal professional degree or residency, providing three years of mentored research support focused on utilizing NHPs as preclinical models to advance understanding and treatment of HIV/AIDS. Successful applicants must hold a full-time appointment at an institution with NHP facilities and commit at least 75% of their professional effort to the program, with funding of up to $100,000 annually for salary and research expenses. Interested applicants should submit their proposals by September 7, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)" aimed at supporting Early Stage Investigators (ESIs) in conducting innovative preclinical research on HIV/AIDS using NHP models. This grant initiative seeks to empower researchers who are within ten years of their terminal degree and have at least two years of postdoctoral experience, enabling them to explore new research directions that align with the NIH Strategic Plan for HIV and HIV-Related Research for FY 2021-2025. The funding provides a maximum of $400,000 over a two-year period, with applications due by September 7, 2025. Interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01 Clinical Trial Not Allowed)" aimed at researching the mechanisms of T-cell involvement in HIV-related central nervous system (CNS) issues. This initiative seeks to develop therapeutic strategies that address T-cell neuro-invasion and HIV-associated neuroinflammation, with a focus on innovative and multidisciplinary approaches utilizing advanced technologies. Approximately $5.5 million is available for this research, with applications opening on February 17, 2025, and a submission deadline of March 18, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.